Search company, investor...

arGentis Pharmaceuticals

Founded Year



Unattributed VC | Alive

Total Raised


Last Raised

$500K | 15 yrs ago

About arGentis Pharmaceuticals

arGentis Pharmaceuticals is a diversified specialty biopharmaceutical company seeking to license and commercialize therapies with demonstrated proof of concept for chronic diseases.

Headquarters Location

20 South Dudley Street Suite 806

Memphis, Tennessee, 38103,

United States


Missing: arGentis Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: arGentis Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest arGentis Pharmaceuticals News

Biotech company promotes exec, develops treatment for rare disease

Apr 18, 2016

Enlarge Ed Henderson has been promoted to vice president of business development for Memphis-based arGentis Pharmaceuticals . Henderson has been the company’s chief marketing officer since 2007. In addition to his promotion, he will also continue to hold his previous position. Enlarge arGentis is developing ARG201, a treatment for systemic scleroderma, an autoimmune disease leading to widespread collagen build-up on the skin and within the vascular structures of internal organs. The disease results in pulmonary hypertension, kidney and gastrointestinal tract failure, pulmonary fibrosis and death. Around 100,000 patients in the U.S. and Europe are treated for the disease annually, but there are no approved therapies for its causes. ARG201 has been granted orphan drug status in the U.S. by the Federal Drug Administration and in the EU by the European Medicines Agency. There are issued and pending patents for ARG201. Michael Sheffield covers bioscience and biotechnology; manufacturing; tourism and hospitality; and sports business. Contact him at .

arGentis Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was arGentis Pharmaceuticals founded?

    arGentis Pharmaceuticals was founded in 2005.

  • Where is arGentis Pharmaceuticals's headquarters?

    arGentis Pharmaceuticals's headquarters is located at 20 South Dudley Street, Memphis.

  • What is arGentis Pharmaceuticals's latest funding round?

    arGentis Pharmaceuticals's latest funding round is Unattributed VC.

  • How much did arGentis Pharmaceuticals raise?

    arGentis Pharmaceuticals raised a total of $500K.

  • Who are the investors of arGentis Pharmaceuticals?

    Investors of arGentis Pharmaceuticals include Innova Memphis.

  • Who are arGentis Pharmaceuticals's competitors?

    Competitors of arGentis Pharmaceuticals include BioMarck Pharmaceuticals, Circassia Holdings, Mpex Pharmaceuticals, Epix Pharmaceuticals, Symphony Medical and 12 more.

Compare arGentis Pharmaceuticals to Competitors

Deltanoid Pharmaceuticals

Deltanoid Pharmaceuticals is a clinical stage biopharmaceutical company with a vision focused on unlocking the power of the vitamin D receptor (VDR) to transform health outcomes for patients with diseases of the kidney, bone, and skin.

Need Pharma

NeED Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of anti-infective drugs for the treatment of serious and neglected infectious diseases, where a large unmet medical need and market opportunity are clearly present.

Sound Pharmaceuticals

Sound Pharmaceuticals (SPI) is a biopharmaceutical company that develops prescription drugs that will enable doctors and patients to prevent and treat hearing loss, a disease that affects over 30 to 40 million Americans. It was founded in 2002 and is based in Seattle, Washington.


NovoBiotic has developed a method for growing previously "unculturable" microorganisms in the laboratory. The company is using this proprietary technology as a platform for antibiotic discovery.

Myelos Corporation

Savient Pharmaceuticals is a specialty biopharmaceutical company engaged in developing and commercializing pharmaceutical products that target unmet medical needs in rheumatology and other specialty niche medical markets. The company's focus is on the company's biologic product candidate, Puricase (pegloticase) that has been developed for treatment-failure gout (TFG).

Inflazyme Pharmaceuticals

Inflazyme Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of respiratory and inflammatory diseases. The company's core focus is medicinal chemistry based, orally active, small molecules aimed at treating unmet medical needs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.